Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 149-154

  Tsuboi, Takashi ^a   Suzuki, Takefumi ^a,b   Bies, Robert R ^c,d,e   Remington, Gary ^e,f   Pollock, Bruce G ^e,f   Mimura, Masaru ^a   Uchida, Hiroyuki ^a,e  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inokashira Hospital   (Japan)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Indiana Clinical and Translational Sciences Institute   (United States)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Dopamine D2 receptor; Maintenance treatment; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; RISPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SCHIZOPHRENIA; SIDE EFFECT; SIMPSON-ANGUS SCALE; SINGLE BLIND PROCEDURE; SOMNOLENCE; AGED; BLOOD; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84929268327     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.03.025     Document Type: Article

References (38)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3(4):247-251.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
3. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Kirshner M.A., Schneider L.S., Bies R.R. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol. 2008, 48(2):157-165.
4. Davis J.M. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am. J. Psychiatry 1975, 132(12):1237-1245.
5. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33(6):766-771.
6. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992, 49(7):538-544.
7. Feng Y., Pollock B.G., Coley K., Marder S., Miller D., Kirshner M., Aravagiri M., Schneider L., Bies R.R. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br. J. Clin. Pharmacol. 2008, 66(5):629-639.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, Dept. of Health, Education, and Welfare, Washington, DC.
9. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl. 2003, (416):16-23.
10. Ikai S., Remington G., Suzuki T., Takeuchi H., Tsuboi T., Den R., Hirano J., Tsunoda K., Nishimoto M., Watanabe K., Mimura M., Mamo D., Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J. Clin. Psychiatry 2012, 73(8):1147-1152.
11. Jeste D.V., Caligiuri M.P., Paulsen J.S., Heaton R.K., Lacro J.P., Harris M.J., Bailey A., Fell R.L., McAdams L.A. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry 1995, 52(9):756-765.
12. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
13. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
14. Lemmens P., Brecher M., Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr. Scand. 1999, 99(3):160-170.
15. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Davis J.M. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2012, 5:CD008016.
16. Mizuno Y., Bies R.R., Remington G., Mamo D.C., Suzuki T., Pollock B.G., Tsuboi T., Watanabe K., Mimura M., Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 37(1):182-187.
17. Moriguchi S., Bies R.R., Remington G., Suzuki T., Mamo D.C., Watanabe K., Mimura M., Pollock B.G., Uchida H. Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J. Clin. Psychopharmacol. 2013, 33(5):682-685.
18. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
19. Nyberg S., Farde L., Halldin C., Dahl M.L., Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 1995, 152(2):173-178.
20. Rasmussen H.B., Timm S., Wang A.G., Soeby K., Lublin H., Fenger M., Hemmingsen R., Werge T. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am. J. Psychiatry 2006, 163(3):507-511.
21. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009, 360(3):225-235.
22. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(8):1042-1048.
23. Sakurai H., Bies R.R., Stroup S.T., Keefe R.S., Rajji T.K., Suzuki T., Mamo D.C., Pollock B.G., Watanabe K., Mimura M., Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr. Bull. 2013, 39(3):564-574.
24. Sheiner L.B., Rosenberg B., Marathe V.V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 1977, 5(5):445-479.
25. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
26. Takeuchi H., Suzuki T., Bies R.R., Remington G., Mamo D.C., Pollock B.G., Mimura M., Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophr. Res. 2013, 150(2-3):373-379.
27. Tsuboi T., Bies R.R., Suzuki T., Mamo D.C., Pollock B.G., Graff-Guerrero A., Mimura M., Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:178-182.
28. Tsuboi T., Suzuki T., Tada M., Hirano J., Nomura K., Pollock B.G., Bies R.R., Nakajima S., Takeuchi H., Mimura M., Uchida H. Predicting antipsychotic plasma concentration of olanzapine associated with dosage change: a population pharmacokinetic study. 23rd Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology, Okinawa 2013.
29. Uchida H., Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J. Clin. Psychopharmacol 2014, 34:728-735.
30. Uchida H., Mamo D.C., Kapur S., Labelle A., Shammi C., Mannaert E.J., Mann S.W., Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry 2008, 69(8):1281-1286.
31. Uchida H., Mamo D.C., Mulsant B.H., Pollock B.G., Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J. Clin. Psychiatry 2009, 70:397-405.
32. Uchida H., Kapur S., Mulsant B.H., Graff-Guerrero A., Pollock B.G., Mamo D.C. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am. J. Geriatr. Psychiatry 2009, 17(3):255-263.
33. Uchida H., Pollock B.G., Bies R.R., Mamo D.C. Predicting age-specific dosing of antipsychotics. Clin. Pharmacol. Ther. 2009, 86(4):360-362.
34. Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr. Bull. 2011, 37(4):788-799.
35. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(4):497-502.
36. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D(2) receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(3):318-325.
37. Uchida H., Mamo D.C., Pollock B.G., Suzuki T., Tsunoda K., Watanabe K., Mimura M., Bies R.R. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther. Drug Monit. 2012, 34(2):182-187.
38. Uchida H., Bies R.R., Suzuki T., Graff-Guerrero A., Pollock B.G., Mulsant B.H., Mamo D.C. Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: a pilot PET study. 3rd Congress of the Asian College of Neuropsychopharmacology, Beijing 2013.